Találati lista | Tudóstér

001-es BibID:	BIBFORM036727
Első szerző:	Gluud, Christian
Cím:	Typical investigational medicinal products follow relatively uniform regulations in 10 European Clinical Research Infrastructures Network (ECRIN) countries / Christian Gluud, Christine Kubiak, Kate Whitfield, Jane Byrne, Karl-Heinz Huemer, Steffen Thirstrup, Christian Libersa, Béatrice Barraud, Xina Grählert, Gabriele Dreier, Sebastian Geismann, Wolfgang Kuchinke, Zsuzsa Temesvari, Gyorgy Blasko, Gabriella Kardos, Timothy O'Brien, Margaret Cooney, Siobhan Gaynor, Arrigo Schieppati, Fernando de Andres, Nuria Sanz, German Kreis, Charlotte Asker-Hagelberg, Hanna Johansson, Sue Bourne, Adeeba Asghar, Jean-Marc Husson, Jacques Demotes-Mainard
Dátum:	2012
ISSN:	1745-6215
Megjegyzések:	Background In order to facilitate multinational clinical research, regulatory requirements need to become international and harmonised. The EU introduced the Directive 2001/20/EC in 2004, regulating investigational medicinal products in Europe. Methods We conducted a survey in order to identify the national regulatory requirements for major categories of clinical research in ten European Clinical Research Infrastructures Network (ECRIN) countries-Austria, Denmark, France, Germany, Hungary, Ireland, Italy, Spain, Sweden, and United Kingdom-covering approximately 70% of the EU population. Here we describe the results for regulatory requirements for typical investigational medicinal products, in the ten countries. Results Our results show that the ten countries have fairly harmonised definitions of typical investigational medicinal products. Clinical trials assessing typical investigational medicinal products require authorisation from a national competent authority in each of the countries surveyed. The opinion of the competent authorities is communicated to the trial sponsor within the same timelines, i.e., no more than 60 days, in all ten countries. The authority to which the application has to be sent to in the different countries is not fully harmonised. Conclusion The Directive 2001/20/EC defined the term 'investigational medicinal product' and all regulatory requirements described therein are applicable to investigational medicinal products. Our survey showed, however, that those requirements had been adopted in ten European countries, not for investigational medicinal products overall, but rather a narrower category which we term 'typical' investigational medicinal products. The result is partial EU harmonisation of requirements and a relatively navigable landscape for the sponsor regarding typical investigational medicinal products.
Tárgyszavak:	Orvostudományok Gyógyszerészeti tudományok idegen nyelvű folyóiratközlemény külföldi lapban külföldön készült közlemény
Megjelenés:	Trials (electronic resources). - 13 : 27 (2012), p. 1-8. -
További szerzők:	Kubiak, Christine Whitfield, Kate Byrne, Jane Huemer, Karl-Heinz Thirstrup, Steffen Libersa, Christian Barraud, Béatrice Grählert, Xina Dreier, Gabriele Geismann, Sebastian Kuchinke, Wolfgang Temesvári Zsuzsa Kardos Gabriella O'Brien, Timothy Cooney, Margaret Gaynor, Siobhan Schieppati, Arrigo Andres-Trelles, Fernando de Sanz, Nuria Kreis, German Asker-Hagelberg, Charlotte Johansson, Hanna Bourne, Sue Asghar, Adeeba Husson, Jean-Marc Demotes-Mainard, Jacques Blaskó György (1947-) (belgyógyász, klinikai farmakológus)
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI
Borító:
Saját polcon: